nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—CYP3A4—Rivastigmine—Alzheimer's disease	0.142	0.432	CbGbCtD
Everolimus—CYP3A4—Donepezil—Alzheimer's disease	0.114	0.345	CbGbCtD
Everolimus—CYP3A4—Galantamine—Alzheimer's disease	0.0733	0.223	CbGbCtD
Everolimus—MTOR—blood vessel—Alzheimer's disease	0.00903	0.176	CbGeAlD
Everolimus—Tacrolimus—PPP3CA—Alzheimer's disease	0.00762	0.895	CrCbGaD
Everolimus—MTOR—embryo—Alzheimer's disease	0.00539	0.105	CbGeAlD
Everolimus—MTOR—forebrain—Alzheimer's disease	0.00477	0.0929	CbGeAlD
Everolimus—MTOR—telencephalon—Alzheimer's disease	0.00438	0.0854	CbGeAlD
Everolimus—FKBP1A—forebrain—Alzheimer's disease	0.00429	0.0835	CbGeAlD
Everolimus—FKBP1A—telencephalon—Alzheimer's disease	0.00394	0.0768	CbGeAlD
Everolimus—MTOR—nervous system—Alzheimer's disease	0.00259	0.0504	CbGeAlD
Everolimus—MTOR—central nervous system—Alzheimer's disease	0.00249	0.0485	CbGeAlD
Everolimus—MTOR—cerebellum—Alzheimer's disease	0.00243	0.0474	CbGeAlD
Everolimus—FKBP1A—nervous system—Alzheimer's disease	0.00233	0.0453	CbGeAlD
Everolimus—FKBP1A—central nervous system—Alzheimer's disease	0.00224	0.0437	CbGeAlD
Everolimus—FKBP1A—cerebellum—Alzheimer's disease	0.00219	0.0427	CbGeAlD
Everolimus—MTOR—brain—Alzheimer's disease	0.00198	0.0385	CbGeAlD
Everolimus—FKBP1A—brain—Alzheimer's disease	0.00178	0.0347	CbGeAlD
Everolimus—Temsirolimus—CYP2D6—Alzheimer's disease	0.000892	0.105	CrCbGaD
Everolimus—CYP3A4—nervous system—Alzheimer's disease	0.000761	0.0148	CbGeAlD
Everolimus—CYP3A4—central nervous system—Alzheimer's disease	0.000732	0.0143	CbGeAlD
Everolimus—Hepatobiliary disease—Rivastigmine—Alzheimer's disease	0.000423	0.00104	CcSEcCtD
Everolimus—Dry mouth—Galantamine—Alzheimer's disease	0.000423	0.00104	CcSEcCtD
Everolimus—Epistaxis—Rivastigmine—Alzheimer's disease	0.000422	0.00104	CcSEcCtD
Everolimus—Sinusitis—Rivastigmine—Alzheimer's disease	0.00042	0.00103	CcSEcCtD
Everolimus—Haemoglobin—Memantine—Alzheimer's disease	0.000413	0.00102	CcSEcCtD
Everolimus—Rhinitis—Memantine—Alzheimer's disease	0.000412	0.00101	CcSEcCtD
Everolimus—Haemorrhage—Memantine—Alzheimer's disease	0.000411	0.00101	CcSEcCtD
Everolimus—Hepatitis—Memantine—Alzheimer's disease	0.000411	0.00101	CcSEcCtD
Everolimus—Hypoaesthesia—Memantine—Alzheimer's disease	0.000409	0.00101	CcSEcCtD
Everolimus—Hallucination—Memantine—Alzheimer's disease	0.000409	0.00101	CcSEcCtD
Everolimus—Shock—Galantamine—Alzheimer's disease	0.000408	0.00101	CcSEcCtD
Everolimus—Pharyngitis—Memantine—Alzheimer's disease	0.000408	0.001	CcSEcCtD
Everolimus—Nervous system disorder—Galantamine—Alzheimer's disease	0.000407	0.001	CcSEcCtD
Everolimus—Thrombocytopenia—Galantamine—Alzheimer's disease	0.000406	0.001	CcSEcCtD
Everolimus—Chills—Donepezil—Alzheimer's disease	0.000406	0.001	CcSEcCtD
Everolimus—Urinary tract disorder—Memantine—Alzheimer's disease	0.000406	0.001	CcSEcCtD
Everolimus—Tachycardia—Galantamine—Alzheimer's disease	0.000405	0.000998	CcSEcCtD
Everolimus—Oedema peripheral—Memantine—Alzheimer's disease	0.000405	0.000997	CcSEcCtD
Everolimus—Haemoglobin—Rivastigmine—Alzheimer's disease	0.000404	0.000995	CcSEcCtD
Everolimus—Connective tissue disorder—Memantine—Alzheimer's disease	0.000404	0.000995	CcSEcCtD
Everolimus—Rhinitis—Rivastigmine—Alzheimer's disease	0.000403	0.000993	CcSEcCtD
Everolimus—Skin disorder—Galantamine—Alzheimer's disease	0.000403	0.000993	CcSEcCtD
Everolimus—Urethral disorder—Memantine—Alzheimer's disease	0.000403	0.000992	CcSEcCtD
Everolimus—Haemorrhage—Rivastigmine—Alzheimer's disease	0.000402	0.00099	CcSEcCtD
Everolimus—Hepatitis—Rivastigmine—Alzheimer's disease	0.000402	0.00099	CcSEcCtD
Everolimus—Hyperhidrosis—Galantamine—Alzheimer's disease	0.000401	0.000988	CcSEcCtD
Everolimus—Hallucination—Rivastigmine—Alzheimer's disease	0.0004	0.000985	CcSEcCtD
Everolimus—Hypoaesthesia—Rivastigmine—Alzheimer's disease	0.0004	0.000985	CcSEcCtD
Everolimus—Alopecia—Donepezil—Alzheimer's disease	0.0004	0.000985	CcSEcCtD
Everolimus—Pharyngitis—Rivastigmine—Alzheimer's disease	0.000399	0.000983	CcSEcCtD
Everolimus—Urinary tract disorder—Rivastigmine—Alzheimer's disease	0.000397	0.000978	CcSEcCtD
Everolimus—Mental disorder—Donepezil—Alzheimer's disease	0.000396	0.000977	CcSEcCtD
Everolimus—Oedema peripheral—Rivastigmine—Alzheimer's disease	0.000396	0.000976	CcSEcCtD
Everolimus—Anorexia—Galantamine—Alzheimer's disease	0.000395	0.000974	CcSEcCtD
Everolimus—Connective tissue disorder—Rivastigmine—Alzheimer's disease	0.000395	0.000973	CcSEcCtD
Everolimus—Urethral disorder—Rivastigmine—Alzheimer's disease	0.000394	0.000971	CcSEcCtD
Everolimus—Malnutrition—Donepezil—Alzheimer's disease	0.000394	0.000971	CcSEcCtD
Everolimus—Erythema—Donepezil—Alzheimer's disease	0.000394	0.000971	CcSEcCtD
Everolimus—Flatulence—Donepezil—Alzheimer's disease	0.000388	0.000956	CcSEcCtD
Everolimus—Hypotension—Galantamine—Alzheimer's disease	0.000388	0.000955	CcSEcCtD
Everolimus—Dysgeusia—Donepezil—Alzheimer's disease	0.000386	0.00095	CcSEcCtD
Everolimus—Eye disorder—Memantine—Alzheimer's disease	0.000384	0.000946	CcSEcCtD
Everolimus—Flushing—Memantine—Alzheimer's disease	0.000381	0.000939	CcSEcCtD
Everolimus—Cardiac disorder—Memantine—Alzheimer's disease	0.000381	0.000939	CcSEcCtD
Everolimus—Back pain—Donepezil—Alzheimer's disease	0.000381	0.000939	CcSEcCtD
Everolimus—Muscle spasms—Donepezil—Alzheimer's disease	0.000379	0.000933	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Galantamine—Alzheimer's disease	0.000378	0.000931	CcSEcCtD
Everolimus—Eye disorder—Rivastigmine—Alzheimer's disease	0.000376	0.000925	CcSEcCtD
Everolimus—Insomnia—Galantamine—Alzheimer's disease	0.000375	0.000924	CcSEcCtD
Everolimus—Cardiac disorder—Rivastigmine—Alzheimer's disease	0.000373	0.000919	CcSEcCtD
Everolimus—Flushing—Rivastigmine—Alzheimer's disease	0.000373	0.000919	CcSEcCtD
Everolimus—Angiopathy—Memantine—Alzheimer's disease	0.000373	0.000918	CcSEcCtD
Everolimus—Paraesthesia—Galantamine—Alzheimer's disease	0.000373	0.000918	CcSEcCtD
Everolimus—Vision blurred—Donepezil—Alzheimer's disease	0.000371	0.000915	CcSEcCtD
Everolimus—Immune system disorder—Memantine—Alzheimer's disease	0.000371	0.000914	CcSEcCtD
Everolimus—Mediastinal disorder—Memantine—Alzheimer's disease	0.00037	0.000912	CcSEcCtD
Everolimus—Tremor—Donepezil—Alzheimer's disease	0.000369	0.000909	CcSEcCtD
Everolimus—Somnolence—Galantamine—Alzheimer's disease	0.000369	0.000909	CcSEcCtD
Everolimus—Chills—Memantine—Alzheimer's disease	0.000369	0.000908	CcSEcCtD
Everolimus—Ill-defined disorder—Donepezil—Alzheimer's disease	0.000366	0.000901	CcSEcCtD
Everolimus—Dyspepsia—Galantamine—Alzheimer's disease	0.000365	0.0009	CcSEcCtD
Everolimus—Angiopathy—Rivastigmine—Alzheimer's disease	0.000365	0.000898	CcSEcCtD
Everolimus—Anaemia—Donepezil—Alzheimer's disease	0.000364	0.000897	CcSEcCtD
Everolimus—Alopecia—Memantine—Alzheimer's disease	0.000363	0.000895	CcSEcCtD
Everolimus—Mediastinal disorder—Rivastigmine—Alzheimer's disease	0.000362	0.000893	CcSEcCtD
Everolimus—Agitation—Donepezil—Alzheimer's disease	0.000362	0.000892	CcSEcCtD
Everolimus—Chills—Rivastigmine—Alzheimer's disease	0.000361	0.000889	CcSEcCtD
Everolimus—Decreased appetite—Galantamine—Alzheimer's disease	0.000361	0.000888	CcSEcCtD
Everolimus—Mental disorder—Memantine—Alzheimer's disease	0.00036	0.000887	CcSEcCtD
Everolimus—Gastrointestinal disorder—Galantamine—Alzheimer's disease	0.000358	0.000882	CcSEcCtD
Everolimus—Malnutrition—Memantine—Alzheimer's disease	0.000358	0.000881	CcSEcCtD
Everolimus—Fatigue—Galantamine—Alzheimer's disease	0.000358	0.000881	CcSEcCtD
Everolimus—Malaise—Donepezil—Alzheimer's disease	0.000355	0.000875	CcSEcCtD
Everolimus—Alopecia—Rivastigmine—Alzheimer's disease	0.000355	0.000875	CcSEcCtD
Everolimus—Constipation—Galantamine—Alzheimer's disease	0.000355	0.000874	CcSEcCtD
Everolimus—Syncope—Donepezil—Alzheimer's disease	0.000353	0.00087	CcSEcCtD
Everolimus—Flatulence—Memantine—Alzheimer's disease	0.000352	0.000868	CcSEcCtD
Everolimus—Mental disorder—Rivastigmine—Alzheimer's disease	0.000352	0.000868	CcSEcCtD
Everolimus—Dysgeusia—Memantine—Alzheimer's disease	0.00035	0.000863	CcSEcCtD
Everolimus—Malnutrition—Rivastigmine—Alzheimer's disease	0.00035	0.000862	CcSEcCtD
Everolimus—Erythema—Rivastigmine—Alzheimer's disease	0.00035	0.000862	CcSEcCtD
Everolimus—Loss of consciousness—Donepezil—Alzheimer's disease	0.000346	0.000853	CcSEcCtD
Everolimus—Back pain—Memantine—Alzheimer's disease	0.000346	0.000852	CcSEcCtD
Everolimus—Flatulence—Rivastigmine—Alzheimer's disease	0.000345	0.000849	CcSEcCtD
Everolimus—Cough—Donepezil—Alzheimer's disease	0.000344	0.000847	CcSEcCtD
Everolimus—Dysgeusia—Rivastigmine—Alzheimer's disease	0.000343	0.000844	CcSEcCtD
Everolimus—Feeling abnormal—Galantamine—Alzheimer's disease	0.000342	0.000842	CcSEcCtD
Everolimus—Convulsion—Donepezil—Alzheimer's disease	0.000341	0.000841	CcSEcCtD
Everolimus—Hypertension—Donepezil—Alzheimer's disease	0.00034	0.000838	CcSEcCtD
Everolimus—Gastrointestinal pain—Galantamine—Alzheimer's disease	0.000339	0.000836	CcSEcCtD
Everolimus—Back pain—Rivastigmine—Alzheimer's disease	0.000338	0.000834	CcSEcCtD
Everolimus—Vision blurred—Memantine—Alzheimer's disease	0.000337	0.00083	CcSEcCtD
Everolimus—Muscle spasms—Rivastigmine—Alzheimer's disease	0.000336	0.000829	CcSEcCtD
Everolimus—Chest pain—Donepezil—Alzheimer's disease	0.000335	0.000826	CcSEcCtD
Everolimus—Myalgia—Donepezil—Alzheimer's disease	0.000335	0.000826	CcSEcCtD
Everolimus—Arthralgia—Donepezil—Alzheimer's disease	0.000335	0.000826	CcSEcCtD
Everolimus—Tremor—Memantine—Alzheimer's disease	0.000335	0.000826	CcSEcCtD
Everolimus—Anxiety—Donepezil—Alzheimer's disease	0.000334	0.000823	CcSEcCtD
Everolimus—Ill-defined disorder—Memantine—Alzheimer's disease	0.000332	0.000818	CcSEcCtD
Everolimus—Discomfort—Donepezil—Alzheimer's disease	0.000331	0.000816	CcSEcCtD
Everolimus—Anaemia—Memantine—Alzheimer's disease	0.000331	0.000814	CcSEcCtD
Everolimus—Vision blurred—Rivastigmine—Alzheimer's disease	0.00033	0.000812	CcSEcCtD
Everolimus—Agitation—Memantine—Alzheimer's disease	0.000329	0.00081	CcSEcCtD
Everolimus—Dry mouth—Donepezil—Alzheimer's disease	0.000328	0.000808	CcSEcCtD
Everolimus—Abdominal pain—Galantamine—Alzheimer's disease	0.000328	0.000808	CcSEcCtD
Everolimus—Body temperature increased—Galantamine—Alzheimer's disease	0.000328	0.000808	CcSEcCtD
Everolimus—Tremor—Rivastigmine—Alzheimer's disease	0.000328	0.000808	CcSEcCtD
Everolimus—Ill-defined disorder—Rivastigmine—Alzheimer's disease	0.000325	0.0008	CcSEcCtD
Everolimus—Anaemia—Rivastigmine—Alzheimer's disease	0.000323	0.000797	CcSEcCtD
Everolimus—Malaise—Memantine—Alzheimer's disease	0.000323	0.000795	CcSEcCtD
Everolimus—Agitation—Rivastigmine—Alzheimer's disease	0.000322	0.000792	CcSEcCtD
Everolimus—Oedema—Donepezil—Alzheimer's disease	0.000322	0.000792	CcSEcCtD
Everolimus—Syncope—Memantine—Alzheimer's disease	0.000321	0.00079	CcSEcCtD
Everolimus—Leukopenia—Memantine—Alzheimer's disease	0.00032	0.000789	CcSEcCtD
Everolimus—Infection—Donepezil—Alzheimer's disease	0.000319	0.000787	CcSEcCtD
Everolimus—Shock—Donepezil—Alzheimer's disease	0.000316	0.000779	CcSEcCtD
Everolimus—Palpitations—Memantine—Alzheimer's disease	0.000316	0.000779	CcSEcCtD
Everolimus—Malaise—Rivastigmine—Alzheimer's disease	0.000316	0.000777	CcSEcCtD
Everolimus—Nervous system disorder—Donepezil—Alzheimer's disease	0.000315	0.000777	CcSEcCtD
Everolimus—Thrombocytopenia—Donepezil—Alzheimer's disease	0.000315	0.000776	CcSEcCtD
Everolimus—Loss of consciousness—Memantine—Alzheimer's disease	0.000314	0.000775	CcSEcCtD
Everolimus—Syncope—Rivastigmine—Alzheimer's disease	0.000314	0.000773	CcSEcCtD
Everolimus—Cough—Memantine—Alzheimer's disease	0.000312	0.000769	CcSEcCtD
Everolimus—Hyperhidrosis—Donepezil—Alzheimer's disease	0.000311	0.000766	CcSEcCtD
Everolimus—Convulsion—Memantine—Alzheimer's disease	0.00031	0.000764	CcSEcCtD
Everolimus—Palpitations—Rivastigmine—Alzheimer's disease	0.000309	0.000762	CcSEcCtD
Everolimus—Hypertension—Memantine—Alzheimer's disease	0.000309	0.000761	CcSEcCtD
Everolimus—Loss of consciousness—Rivastigmine—Alzheimer's disease	0.000308	0.000758	CcSEcCtD
Everolimus—Anorexia—Donepezil—Alzheimer's disease	0.000306	0.000755	CcSEcCtD
Everolimus—Hypersensitivity—Galantamine—Alzheimer's disease	0.000306	0.000753	CcSEcCtD
Everolimus—Cough—Rivastigmine—Alzheimer's disease	0.000305	0.000752	CcSEcCtD
Everolimus—Arthralgia—Memantine—Alzheimer's disease	0.000305	0.00075	CcSEcCtD
Everolimus—Chest pain—Memantine—Alzheimer's disease	0.000305	0.00075	CcSEcCtD
Everolimus—Myalgia—Memantine—Alzheimer's disease	0.000305	0.00075	CcSEcCtD
Everolimus—Anxiety—Memantine—Alzheimer's disease	0.000303	0.000748	CcSEcCtD
Everolimus—Convulsion—Rivastigmine—Alzheimer's disease	0.000303	0.000747	CcSEcCtD
Everolimus—Hypertension—Rivastigmine—Alzheimer's disease	0.000302	0.000744	CcSEcCtD
Everolimus—Discomfort—Memantine—Alzheimer's disease	0.000301	0.000741	CcSEcCtD
Everolimus—Hypotension—Donepezil—Alzheimer's disease	0.0003	0.00074	CcSEcCtD
Everolimus—Arthralgia—Rivastigmine—Alzheimer's disease	0.000298	0.000734	CcSEcCtD
Everolimus—Chest pain—Rivastigmine—Alzheimer's disease	0.000298	0.000734	CcSEcCtD
Everolimus—Myalgia—Rivastigmine—Alzheimer's disease	0.000298	0.000734	CcSEcCtD
Everolimus—Dry mouth—Memantine—Alzheimer's disease	0.000298	0.000734	CcSEcCtD
Everolimus—Asthenia—Galantamine—Alzheimer's disease	0.000298	0.000733	CcSEcCtD
Everolimus—Anxiety—Rivastigmine—Alzheimer's disease	0.000297	0.000731	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Rivastigmine—Alzheimer's disease	0.000296	0.000729	CcSEcCtD
Everolimus—Discomfort—Rivastigmine—Alzheimer's disease	0.000294	0.000725	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Donepezil—Alzheimer's disease	0.000293	0.000722	CcSEcCtD
Everolimus—Oedema—Memantine—Alzheimer's disease	0.000292	0.000719	CcSEcCtD
Everolimus—Dry mouth—Rivastigmine—Alzheimer's disease	0.000291	0.000718	CcSEcCtD
Everolimus—Insomnia—Donepezil—Alzheimer's disease	0.000291	0.000716	CcSEcCtD
Everolimus—Infection—Memantine—Alzheimer's disease	0.00029	0.000714	CcSEcCtD
Everolimus—Paraesthesia—Donepezil—Alzheimer's disease	0.000289	0.000711	CcSEcCtD
Everolimus—Shock—Memantine—Alzheimer's disease	0.000287	0.000708	CcSEcCtD
Everolimus—Dyspnoea—Donepezil—Alzheimer's disease	0.000287	0.000706	CcSEcCtD
Everolimus—Nervous system disorder—Memantine—Alzheimer's disease	0.000286	0.000705	CcSEcCtD
Everolimus—Somnolence—Donepezil—Alzheimer's disease	0.000286	0.000704	CcSEcCtD
Everolimus—Thrombocytopenia—Memantine—Alzheimer's disease	0.000286	0.000704	CcSEcCtD
Everolimus—Oedema—Rivastigmine—Alzheimer's disease	0.000286	0.000704	CcSEcCtD
Everolimus—Tachycardia—Memantine—Alzheimer's disease	0.000285	0.000702	CcSEcCtD
Everolimus—Diarrhoea—Galantamine—Alzheimer's disease	0.000284	0.000699	CcSEcCtD
Everolimus—Infection—Rivastigmine—Alzheimer's disease	0.000284	0.000699	CcSEcCtD
Everolimus—Skin disorder—Memantine—Alzheimer's disease	0.000284	0.000699	CcSEcCtD
Everolimus—Dyspepsia—Donepezil—Alzheimer's disease	0.000283	0.000697	CcSEcCtD
Everolimus—Hyperhidrosis—Memantine—Alzheimer's disease	0.000282	0.000695	CcSEcCtD
Everolimus—Shock—Rivastigmine—Alzheimer's disease	0.000281	0.000692	CcSEcCtD
Everolimus—Nervous system disorder—Rivastigmine—Alzheimer's disease	0.00028	0.00069	CcSEcCtD
Everolimus—Thrombocytopenia—Rivastigmine—Alzheimer's disease	0.00028	0.000689	CcSEcCtD
Everolimus—Decreased appetite—Donepezil—Alzheimer's disease	0.000279	0.000689	CcSEcCtD
Everolimus—Tachycardia—Rivastigmine—Alzheimer's disease	0.000279	0.000687	CcSEcCtD
Everolimus—Anorexia—Memantine—Alzheimer's disease	0.000278	0.000686	CcSEcCtD
Everolimus—Gastrointestinal disorder—Donepezil—Alzheimer's disease	0.000278	0.000684	CcSEcCtD
Everolimus—Skin disorder—Rivastigmine—Alzheimer's disease	0.000277	0.000683	CcSEcCtD
Everolimus—Fatigue—Donepezil—Alzheimer's disease	0.000277	0.000683	CcSEcCtD
Everolimus—Hyperhidrosis—Rivastigmine—Alzheimer's disease	0.000276	0.00068	CcSEcCtD
Everolimus—Pain—Donepezil—Alzheimer's disease	0.000275	0.000677	CcSEcCtD
Everolimus—Constipation—Donepezil—Alzheimer's disease	0.000275	0.000677	CcSEcCtD
Everolimus—Dizziness—Galantamine—Alzheimer's disease	0.000274	0.000676	CcSEcCtD
Everolimus—Hypotension—Memantine—Alzheimer's disease	0.000273	0.000672	CcSEcCtD
Everolimus—Anorexia—Rivastigmine—Alzheimer's disease	0.000272	0.000671	CcSEcCtD
Everolimus—Hypotension—Rivastigmine—Alzheimer's disease	0.000267	0.000657	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Memantine—Alzheimer's disease	0.000266	0.000655	CcSEcCtD
Everolimus—Feeling abnormal—Donepezil—Alzheimer's disease	0.000265	0.000653	CcSEcCtD
Everolimus—Insomnia—Memantine—Alzheimer's disease	0.000264	0.00065	CcSEcCtD
Everolimus—Vomiting—Galantamine—Alzheimer's disease	0.000264	0.00065	CcSEcCtD
Everolimus—Gastrointestinal pain—Donepezil—Alzheimer's disease	0.000263	0.000648	CcSEcCtD
Everolimus—Paraesthesia—Memantine—Alzheimer's disease	0.000262	0.000646	CcSEcCtD
Everolimus—Rash—Galantamine—Alzheimer's disease	0.000262	0.000644	CcSEcCtD
Everolimus—Dermatitis—Galantamine—Alzheimer's disease	0.000261	0.000644	CcSEcCtD
Everolimus—Dyspnoea—Memantine—Alzheimer's disease	0.00026	0.000641	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Rivastigmine—Alzheimer's disease	0.00026	0.000641	CcSEcCtD
Everolimus—Headache—Galantamine—Alzheimer's disease	0.00026	0.00064	CcSEcCtD
Everolimus—Somnolence—Memantine—Alzheimer's disease	0.00026	0.000639	CcSEcCtD
Everolimus—Insomnia—Rivastigmine—Alzheimer's disease	0.000258	0.000636	CcSEcCtD
Everolimus—Dyspepsia—Memantine—Alzheimer's disease	0.000257	0.000633	CcSEcCtD
Everolimus—Paraesthesia—Rivastigmine—Alzheimer's disease	0.000256	0.000632	CcSEcCtD
Everolimus—Dyspnoea—Rivastigmine—Alzheimer's disease	0.000255	0.000627	CcSEcCtD
Everolimus—Abdominal pain—Donepezil—Alzheimer's disease	0.000254	0.000626	CcSEcCtD
Everolimus—Body temperature increased—Donepezil—Alzheimer's disease	0.000254	0.000626	CcSEcCtD
Everolimus—Somnolence—Rivastigmine—Alzheimer's disease	0.000254	0.000625	CcSEcCtD
Everolimus—Decreased appetite—Memantine—Alzheimer's disease	0.000254	0.000625	CcSEcCtD
Everolimus—Gastrointestinal disorder—Memantine—Alzheimer's disease	0.000252	0.000621	CcSEcCtD
Everolimus—Fatigue—Memantine—Alzheimer's disease	0.000252	0.00062	CcSEcCtD
Everolimus—Dyspepsia—Rivastigmine—Alzheimer's disease	0.000251	0.000619	CcSEcCtD
Everolimus—Pain—Memantine—Alzheimer's disease	0.00025	0.000615	CcSEcCtD
Everolimus—Constipation—Memantine—Alzheimer's disease	0.00025	0.000615	CcSEcCtD
Everolimus—Decreased appetite—Rivastigmine—Alzheimer's disease	0.000248	0.000612	CcSEcCtD
Everolimus—Gastrointestinal disorder—Rivastigmine—Alzheimer's disease	0.000247	0.000607	CcSEcCtD
Everolimus—Nausea—Galantamine—Alzheimer's disease	0.000246	0.000607	CcSEcCtD
Everolimus—Fatigue—Rivastigmine—Alzheimer's disease	0.000246	0.000607	CcSEcCtD
Everolimus—Constipation—Rivastigmine—Alzheimer's disease	0.000244	0.000602	CcSEcCtD
Everolimus—Pain—Rivastigmine—Alzheimer's disease	0.000244	0.000602	CcSEcCtD
Everolimus—Feeling abnormal—Memantine—Alzheimer's disease	0.000241	0.000593	CcSEcCtD
Everolimus—Gastrointestinal pain—Memantine—Alzheimer's disease	0.000239	0.000588	CcSEcCtD
Everolimus—Hypersensitivity—Donepezil—Alzheimer's disease	0.000237	0.000584	CcSEcCtD
Everolimus—Feeling abnormal—Rivastigmine—Alzheimer's disease	0.000235	0.00058	CcSEcCtD
Everolimus—Gastrointestinal pain—Rivastigmine—Alzheimer's disease	0.000234	0.000575	CcSEcCtD
Everolimus—Abdominal pain—Memantine—Alzheimer's disease	0.000231	0.000569	CcSEcCtD
Everolimus—Body temperature increased—Memantine—Alzheimer's disease	0.000231	0.000569	CcSEcCtD
Everolimus—Asthenia—Donepezil—Alzheimer's disease	0.000231	0.000568	CcSEcCtD
Everolimus—Pruritus—Donepezil—Alzheimer's disease	0.000227	0.00056	CcSEcCtD
Everolimus—Abdominal pain—Rivastigmine—Alzheimer's disease	0.000226	0.000556	CcSEcCtD
Everolimus—Body temperature increased—Rivastigmine—Alzheimer's disease	0.000226	0.000556	CcSEcCtD
Everolimus—Diarrhoea—Donepezil—Alzheimer's disease	0.00022	0.000542	CcSEcCtD
Everolimus—Hypersensitivity—Memantine—Alzheimer's disease	0.000215	0.00053	CcSEcCtD
Everolimus—Dizziness—Donepezil—Alzheimer's disease	0.000213	0.000524	CcSEcCtD
Everolimus—Hypersensitivity—Rivastigmine—Alzheimer's disease	0.00021	0.000518	CcSEcCtD
Everolimus—Asthenia—Memantine—Alzheimer's disease	0.000209	0.000516	CcSEcCtD
Everolimus—Pruritus—Memantine—Alzheimer's disease	0.000207	0.000509	CcSEcCtD
Everolimus—Asthenia—Rivastigmine—Alzheimer's disease	0.000205	0.000505	CcSEcCtD
Everolimus—Vomiting—Donepezil—Alzheimer's disease	0.000204	0.000504	CcSEcCtD
Everolimus—Rash—Donepezil—Alzheimer's disease	0.000203	0.000499	CcSEcCtD
Everolimus—Dermatitis—Donepezil—Alzheimer's disease	0.000203	0.000499	CcSEcCtD
Everolimus—Pruritus—Rivastigmine—Alzheimer's disease	0.000202	0.000498	CcSEcCtD
Everolimus—Headache—Donepezil—Alzheimer's disease	0.000201	0.000496	CcSEcCtD
Everolimus—Diarrhoea—Memantine—Alzheimer's disease	0.0002	0.000492	CcSEcCtD
Everolimus—Diarrhoea—Rivastigmine—Alzheimer's disease	0.000195	0.000481	CcSEcCtD
Everolimus—Dizziness—Memantine—Alzheimer's disease	0.000193	0.000476	CcSEcCtD
Everolimus—Nausea—Donepezil—Alzheimer's disease	0.000191	0.00047	CcSEcCtD
Everolimus—Dizziness—Rivastigmine—Alzheimer's disease	0.000189	0.000465	CcSEcCtD
Everolimus—Vomiting—Memantine—Alzheimer's disease	0.000186	0.000457	CcSEcCtD
Everolimus—Rash—Memantine—Alzheimer's disease	0.000184	0.000453	CcSEcCtD
Everolimus—Dermatitis—Memantine—Alzheimer's disease	0.000184	0.000453	CcSEcCtD
Everolimus—Headache—Memantine—Alzheimer's disease	0.000183	0.000451	CcSEcCtD
Everolimus—Vomiting—Rivastigmine—Alzheimer's disease	0.000182	0.000447	CcSEcCtD
Everolimus—Rash—Rivastigmine—Alzheimer's disease	0.00018	0.000444	CcSEcCtD
Everolimus—Dermatitis—Rivastigmine—Alzheimer's disease	0.00018	0.000443	CcSEcCtD
Everolimus—Headache—Rivastigmine—Alzheimer's disease	0.000179	0.000441	CcSEcCtD
Everolimus—Nausea—Memantine—Alzheimer's disease	0.000173	0.000427	CcSEcCtD
Everolimus—Nausea—Rivastigmine—Alzheimer's disease	0.00017	0.000418	CcSEcCtD
Everolimus—CYP3A4—Biological oxidations—CYP2D6—Alzheimer's disease	8.03e-05	0.000392	CbGpPWpGaD
Everolimus—MTOR—Disease—GAPDH—Alzheimer's disease	8.01e-05	0.000391	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—CYP2D6—Alzheimer's disease	7.92e-05	0.000386	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NPS—Alzheimer's disease	7.85e-05	0.000383	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—Alzheimer's disease	7.82e-05	0.000381	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PPP3CA—Alzheimer's disease	7.81e-05	0.000381	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MEF2C—Alzheimer's disease	7.75e-05	0.000378	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTK2B—Alzheimer's disease	7.7e-05	0.000376	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDK5—Alzheimer's disease	7.69e-05	0.000375	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AGER—Alzheimer's disease	7.69e-05	0.000375	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PRKCG—Alzheimer's disease	7.61e-05	0.000371	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—IL6—Alzheimer's disease	7.56e-05	0.000369	CbGpPWpGaD
Everolimus—MTOR—Disease—PSEN2—Alzheimer's disease	7.49e-05	0.000365	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—GAB2—Alzheimer's disease	7.49e-05	0.000365	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NTRK2—Alzheimer's disease	7.49e-05	0.000365	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SST—Alzheimer's disease	7.49e-05	0.000365	CbGpPWpGaD
Everolimus—FKBP1A—Disease—LPL—Alzheimer's disease	7.48e-05	0.000365	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—GSK3A—Alzheimer's disease	7.42e-05	0.000362	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HTR6—Alzheimer's disease	7.4e-05	0.000361	CbGpPWpGaD
Everolimus—MTOR—Disease—CST3—Alzheimer's disease	7.32e-05	0.000357	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—CASP3—Alzheimer's disease	7.31e-05	0.000357	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APP—Alzheimer's disease	7.3e-05	0.000356	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PRKCG—Alzheimer's disease	7.27e-05	0.000355	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—IL6—Alzheimer's disease	7.23e-05	0.000353	CbGpPWpGaD
Everolimus—MTOR—Immune System—INPP5D—Alzheimer's disease	7.2e-05	0.000351	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—MAPK8—Alzheimer's disease	7.17e-05	0.00035	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—IL6—Alzheimer's disease	7.12e-05	0.000347	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—AKT1—Alzheimer's disease	6.97e-05	0.00034	CbGpPWpGaD
Everolimus—MTOR—Immune System—CTSB—Alzheimer's disease	6.93e-05	0.000338	CbGpPWpGaD
Everolimus—MTOR—Immune System—CTSD—Alzheimer's disease	6.9e-05	0.000337	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CCR5—Alzheimer's disease	6.89e-05	0.000336	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PLCB1—Alzheimer's disease	6.89e-05	0.000336	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—AKT1—Alzheimer's disease	6.86e-05	0.000334	CbGpPWpGaD
Everolimus—MTOR—Disease—IAPP—Alzheimer's disease	6.85e-05	0.000334	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—IL6—Alzheimer's disease	6.8e-05	0.000332	CbGpPWpGaD
Everolimus—MTOR—Immune System—PPP3CA—Alzheimer's disease	6.8e-05	0.000332	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—IL6—Alzheimer's disease	6.76e-05	0.00033	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MTHFR—Alzheimer's disease	6.74e-05	0.000329	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—IL6—Alzheimer's disease	6.73e-05	0.000328	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—MAPK8—Alzheimer's disease	6.72e-05	0.000328	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PSENEN—Alzheimer's disease	6.72e-05	0.000328	CbGpPWpGaD
Everolimus—MTOR—Immune System—PTK2B—Alzheimer's disease	6.7e-05	0.000327	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—IL6—Alzheimer's disease	6.7e-05	0.000327	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—AKT1—Alzheimer's disease	6.67e-05	0.000325	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APH1A—Alzheimer's disease	6.63e-05	0.000323	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—VEGFA—Alzheimer's disease	6.62e-05	0.000323	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—Alzheimer's disease	6.6e-05	0.000322	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CALM1—Alzheimer's disease	6.58e-05	0.000321	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—AKT1—Alzheimer's disease	6.57e-05	0.00032	CbGpPWpGaD
Everolimus—MTOR—Immune System—GAB2—Alzheimer's disease	6.52e-05	0.000318	CbGpPWpGaD
Everolimus—MTOR—Immune System—GSK3A—Alzheimer's disease	6.46e-05	0.000315	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NCSTN—Alzheimer's disease	6.45e-05	0.000315	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NGFR—Alzheimer's disease	6.43e-05	0.000313	CbGpPWpGaD
Everolimus—MTOR—Immune System—APP—Alzheimer's disease	6.35e-05	0.00031	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CALM1—Alzheimer's disease	6.32e-05	0.000308	CbGpPWpGaD
Everolimus—MTOR—Disease—ENO1—Alzheimer's disease	6.31e-05	0.000308	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—AKT1—Alzheimer's disease	6.3e-05	0.000307	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—IL6—Alzheimer's disease	6.3e-05	0.000307	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—Alzheimer's disease	6.3e-05	0.000307	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—IL6—Alzheimer's disease	6.3e-05	0.000307	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CALM1—Alzheimer's disease	6.29e-05	0.000307	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LRP1—Alzheimer's disease	6.29e-05	0.000307	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ADAM10—Alzheimer's disease	6.28e-05	0.000306	CbGpPWpGaD
Everolimus—MTOR—Disease—PPP3CA—Alzheimer's disease	6.27e-05	0.000306	CbGpPWpGaD
Everolimus—FKBP1A—Disease—APOE—Alzheimer's disease	6.27e-05	0.000306	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—AKT1—Alzheimer's disease	6.27e-05	0.000306	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—IL6—Alzheimer's disease	6.24e-05	0.000305	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—AKT1—Alzheimer's disease	6.24e-05	0.000304	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—Alzheimer's disease	6.24e-05	0.000304	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CAV1—Alzheimer's disease	6.21e-05	0.000303	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—AKT1—Alzheimer's disease	6.21e-05	0.000303	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—IL6—Alzheimer's disease	6.19e-05	0.000302	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—AKT1—Alzheimer's disease	6.18e-05	0.000301	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—IL6—Alzheimer's disease	6.16e-05	0.000301	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GAL—Alzheimer's disease	6.15e-05	0.0003	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GFAP—Alzheimer's disease	6.15e-05	0.0003	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—Alzheimer's disease	6.09e-05	0.000297	CbGpPWpGaD
Everolimus—MTOR—Disease—GAB2—Alzheimer's disease	6.02e-05	0.000293	CbGpPWpGaD
Everolimus—MTOR—Disease—GSK3A—Alzheimer's disease	5.96e-05	0.000291	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—S100B—Alzheimer's disease	5.94e-05	0.00029	CbGpPWpGaD
Everolimus—MTOR—Disease—APP—Alzheimer's disease	5.86e-05	0.000286	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOS2—Alzheimer's disease	5.84e-05	0.000285	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—AKT1—Alzheimer's disease	5.81e-05	0.000284	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—Alzheimer's disease	5.81e-05	0.000284	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—AKT1—Alzheimer's disease	5.81e-05	0.000284	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOTCH1—Alzheimer's disease	5.79e-05	0.000282	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—AKT1—Alzheimer's disease	5.76e-05	0.000281	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—AKT1—Alzheimer's disease	5.71e-05	0.000279	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—AKT1—Alzheimer's disease	5.68e-05	0.000277	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—GSK3B—Alzheimer's disease	5.68e-05	0.000277	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IGF2—Alzheimer's disease	5.65e-05	0.000276	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CREB1—Alzheimer's disease	5.63e-05	0.000275	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—Alzheimer's disease	5.58e-05	0.000272	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IGF1R—Alzheimer's disease	5.46e-05	0.000267	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—GSK3B—Alzheimer's disease	5.45e-05	0.000266	CbGpPWpGaD
Everolimus—FKBP1A—Disease—GSK3B—Alzheimer's disease	5.43e-05	0.000265	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—A2M—Alzheimer's disease	5.42e-05	0.000264	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CREB1—Alzheimer's disease	5.41e-05	0.000264	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CREB1—Alzheimer's disease	5.39e-05	0.000263	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—AKT1—Alzheimer's disease	5.38e-05	0.000262	CbGpPWpGaD
Everolimus—FKBP1A—Disease—INS—Alzheimer's disease	5.36e-05	0.000261	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PSEN2—Alzheimer's disease	5.25e-05	0.000256	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—LPL—Alzheimer's disease	5.24e-05	0.000256	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MEF2C—Alzheimer's disease	5.19e-05	0.000253	CbGpPWpGaD
Everolimus—MTOR—Immune System—S100B—Alzheimer's disease	5.16e-05	0.000252	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—Alzheimer's disease	5.15e-05	0.000251	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PRKCG—Alzheimer's disease	5.09e-05	0.000248	CbGpPWpGaD
Everolimus—MTOR—Disease—ADAM10—Alzheimer's disease	5.04e-05	0.000246	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—TP53—Alzheimer's disease	5e-05	0.000244	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NGF—Alzheimer's disease	4.96e-05	0.000242	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NPY—Alzheimer's disease	4.83e-05	0.000236	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCR5—Alzheimer's disease	4.83e-05	0.000235	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IAPP—Alzheimer's disease	4.8e-05	0.000234	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—BCL2—Alzheimer's disease	4.73e-05	0.000231	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HTR2A—Alzheimer's disease	4.72e-05	0.00023	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOS3—Alzheimer's disease	4.7e-05	0.000229	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL1A—Alzheimer's disease	4.67e-05	0.000228	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CRH—Alzheimer's disease	4.66e-05	0.000227	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—DHCR24—Alzheimer's disease	4.64e-05	0.000226	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—IL6—Alzheimer's disease	4.58e-05	0.000223	CbGpPWpGaD
Everolimus—MTOR—Immune System—MEF2C—Alzheimer's disease	4.52e-05	0.00022	CbGpPWpGaD
Everolimus—MTOR—Immune System—AGER—Alzheimer's disease	4.48e-05	0.000218	CbGpPWpGaD
Everolimus—MTOR—Immune System—PRKCG—Alzheimer's disease	4.43e-05	0.000216	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NPS—Alzheimer's disease	4.42e-05	0.000215	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CALM1—Alzheimer's disease	4.41e-05	0.000215	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PPP3CA—Alzheimer's disease	4.39e-05	0.000214	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APOE—Alzheimer's disease	4.39e-05	0.000214	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—LEP—Alzheimer's disease	4.39e-05	0.000214	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CAV1—Alzheimer's disease	4.35e-05	0.000212	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTK2B—Alzheimer's disease	4.33e-05	0.000211	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTGS2—Alzheimer's disease	4.3e-05	0.00021	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—IL6—Alzheimer's disease	4.29e-05	0.000209	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GAB2—Alzheimer's disease	4.21e-05	0.000205	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NTRK2—Alzheimer's disease	4.21e-05	0.000205	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SST—Alzheimer's disease	4.21e-05	0.000205	CbGpPWpGaD
Everolimus—MTOR—Disease—LPL—Alzheimer's disease	4.21e-05	0.000205	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ESR1—Alzheimer's disease	4.19e-05	0.000205	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GSK3A—Alzheimer's disease	4.18e-05	0.000204	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—F2—Alzheimer's disease	4.14e-05	0.000202	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APP—Alzheimer's disease	4.1e-05	0.0002	CbGpPWpGaD
Everolimus—MTOR—Disease—PRKCG—Alzheimer's disease	4.09e-05	0.0002	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOTCH1—Alzheimer's disease	4.05e-05	0.000198	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—AKT1—Alzheimer's disease	3.96e-05	0.000193	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CA4—Alzheimer's disease	3.95e-05	0.000193	CbGpPWpGaD
Everolimus—MTOR—Disease—CCR5—Alzheimer's disease	3.88e-05	0.000189	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PLCB1—Alzheimer's disease	3.87e-05	0.000189	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MAPK8—Alzheimer's disease	3.83e-05	0.000187	CbGpPWpGaD
Everolimus—MTOR—Immune System—CALM1—Alzheimer's disease	3.83e-05	0.000187	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—GSK3B—Alzheimer's disease	3.8e-05	0.000186	CbGpPWpGaD
Everolimus—MTOR—Disease—MTHFR—Alzheimer's disease	3.79e-05	0.000185	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CREB1—Alzheimer's disease	3.77e-05	0.000184	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—INS—Alzheimer's disease	3.75e-05	0.000183	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GAPDHS—Alzheimer's disease	3.71e-05	0.000181	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCL2—Alzheimer's disease	3.69e-05	0.00018	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IGF1—Alzheimer's disease	3.63e-05	0.000177	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NGFR—Alzheimer's disease	3.61e-05	0.000176	CbGpPWpGaD
Everolimus—MTOR—Disease—CALM1—Alzheimer's disease	3.54e-05	0.000173	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADAM10—Alzheimer's disease	3.53e-05	0.000172	CbGpPWpGaD
Everolimus—MTOR—Disease—APOE—Alzheimer's disease	3.53e-05	0.000172	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ATP5A1—Alzheimer's disease	3.52e-05	0.000172	CbGpPWpGaD
Everolimus—MTOR—Disease—CAV1—Alzheimer's disease	3.49e-05	0.00017	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLD3—Alzheimer's disease	3.36e-05	0.000164	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—S100B—Alzheimer's disease	3.34e-05	0.000163	CbGpPWpGaD
Everolimus—MTOR—Immune System—GSK3B—Alzheimer's disease	3.31e-05	0.000161	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOS3—Alzheimer's disease	3.29e-05	0.00016	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS2—Alzheimer's disease	3.29e-05	0.00016	CbGpPWpGaD
Everolimus—MTOR—Immune System—CREB1—Alzheimer's disease	3.28e-05	0.00016	CbGpPWpGaD
Everolimus—MTOR—Disease—NOTCH1—Alzheimer's disease	3.25e-05	0.000159	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HSD17B10—Alzheimer's disease	3.22e-05	0.000157	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF2—Alzheimer's disease	3.18e-05	0.000155	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TGFB1—Alzheimer's disease	3.11e-05	0.000152	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP46A1—Alzheimer's disease	3.1e-05	0.000151	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF1R—Alzheimer's disease	3.07e-05	0.00015	CbGpPWpGaD
Everolimus—MTOR—Disease—GSK3B—Alzheimer's disease	3.05e-05	0.000149	CbGpPWpGaD
Everolimus—MTOR—Disease—CREB1—Alzheimer's disease	3.03e-05	0.000148	CbGpPWpGaD
Everolimus—MTOR—Disease—INS—Alzheimer's disease	3.01e-05	0.000147	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ND1—Alzheimer's disease	2.99e-05	0.000146	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LPL—Alzheimer's disease	2.95e-05	0.000144	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MEF2C—Alzheimer's disease	2.92e-05	0.000142	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PRKCG—Alzheimer's disease	2.86e-05	0.00014	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CASP3—Alzheimer's disease	2.79e-05	0.000136	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NGF—Alzheimer's disease	2.79e-05	0.000136	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2—Alzheimer's disease	2.75e-05	0.000134	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCR5—Alzheimer's disease	2.71e-05	0.000132	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HTR2A—Alzheimer's disease	2.66e-05	0.00013	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS3—Alzheimer's disease	2.64e-05	0.000129	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK8—Alzheimer's disease	2.57e-05	0.000125	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CALM1—Alzheimer's disease	2.48e-05	0.000121	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LEP—Alzheimer's disease	2.47e-05	0.00012	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOE—Alzheimer's disease	2.47e-05	0.00012	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—Alzheimer's disease	2.45e-05	0.000119	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CAV1—Alzheimer's disease	2.45e-05	0.000119	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL1B—Alzheimer's disease	2.43e-05	0.000119	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—Alzheimer's disease	2.42e-05	0.000118	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—Alzheimer's disease	2.37e-05	0.000116	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ESR1—Alzheimer's disease	2.36e-05	0.000115	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—Alzheimer's disease	2.34e-05	0.000114	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—F2—Alzheimer's disease	2.33e-05	0.000114	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOTCH1—Alzheimer's disease	2.28e-05	0.000111	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT1—Alzheimer's disease	2.26e-05	0.00011	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK8—Alzheimer's disease	2.23e-05	0.000109	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TGFB1—Alzheimer's disease	2.18e-05	0.000106	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT1—Alzheimer's disease	2.17e-05	0.000106	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT1—Alzheimer's disease	2.16e-05	0.000105	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GSK3B—Alzheimer's disease	2.14e-05	0.000104	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CREB1—Alzheimer's disease	2.12e-05	0.000103	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—INS—Alzheimer's disease	2.11e-05	0.000103	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL2—Alzheimer's disease	2.08e-05	0.000101	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF1—Alzheimer's disease	2.04e-05	9.96e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TPI1—Alzheimer's disease	1.93e-05	9.4e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CHAT—Alzheimer's disease	1.93e-05	9.4e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOS3—Alzheimer's disease	1.85e-05	9.03e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MAOB—Alzheimer's disease	1.85e-05	9.02e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—Alzheimer's disease	1.79e-05	8.74e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GAPDH—Alzheimer's disease	1.78e-05	8.68e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—TGFB1—Alzheimer's disease	1.75e-05	8.52e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—A2M—Alzheimer's disease	1.72e-05	8.38e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—Alzheimer's disease	1.64e-05	8e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CASP3—Alzheimer's disease	1.57e-05	7.66e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT1—Alzheimer's disease	1.51e-05	7.38e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ACHE—Alzheimer's disease	1.49e-05	7.29e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—INPP5D—Alzheimer's disease	1.48e-05	7.21e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK8—Alzheimer's disease	1.44e-05	7.04e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—Alzheimer's disease	1.43e-05	6.96e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS1—Alzheimer's disease	1.4e-05	6.83e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ENO1—Alzheimer's disease	1.4e-05	6.83e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP2D6—Alzheimer's disease	1.37e-05	6.7e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—Alzheimer's disease	1.33e-05	6.5e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—Alzheimer's disease	1.32e-05	6.42e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT1—Alzheimer's disease	1.32e-05	6.42e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—BCHE—Alzheimer's disease	1.3e-05	6.35e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLCB1—Alzheimer's disease	1.23e-05	5.99e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFB1—Alzheimer's disease	1.22e-05	5.97e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT1—Alzheimer's disease	1.21e-05	5.92e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCA1—Alzheimer's disease	1.19e-05	5.81e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARGC1A—Alzheimer's disease	1.03e-05	5.01e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HMOX1—Alzheimer's disease	1.02e-05	4.98e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—Alzheimer's disease	1.01e-05	4.91e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LPL—Alzheimer's disease	9.35e-06	4.56e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—Alzheimer's disease	9.22e-06	4.5e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT1—Alzheimer's disease	8.5e-06	4.15e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTHFR—Alzheimer's disease	8.41e-06	4.1e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CALM1—Alzheimer's disease	7.86e-06	3.84e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOE—Alzheimer's disease	7.83e-06	3.82e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CAV1—Alzheimer's disease	7.76e-06	3.79e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARG—Alzheimer's disease	6.82e-06	3.33e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—INS—Alzheimer's disease	6.69e-06	3.26e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NOS3—Alzheimer's disease	5.87e-06	2.86e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—Alzheimer's disease	5.37e-06	2.62e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKT1—Alzheimer's disease	2.7e-06	1.32e-05	CbGpPWpGaD
